BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 9:25:00 AM | Browse: 783 | Download: 785
 |
Received |
|
2013-06-28 11:23 |
 |
Peer-Review Started |
|
2013-06-28 17:28 |
 |
To Make the First Decision |
|
2013-07-19 08:38 |
 |
Return for Revision |
|
2013-07-19 22:14 |
 |
Revised |
|
2013-08-26 22:43 |
 |
Second Decision |
|
2013-10-16 09:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-10-16 10:32 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-12-30 17:04 |
 |
Publish the Manuscript Online |
|
2013-12-31 17:17 |
Category |
Transplantation |
Manuscript Type |
Review |
Article Title |
Novel immunosuppressive agents in kidney transplantation
|
Manuscript Source |
Invited Manuscript |
All Author List |
Karen L Hardinger and Daniel C Brennan |
Funding Agency and Grant Number |
|
Corresponding Author |
Karen L Hardinger, PharmD, BCPS, Clinical Associate Professor of Pharmacy Practice, Department of Pharmacy Practice and Administration, University of Missouri-Kansas City, 2464 Charlotte Street, Rm 2241, Kansas City, MO 64108, United States. hardingerk@umkc.edu |
Key Words |
Review; Immunosuppression; Investigational agents; Renal/kidney transplant |
Core Tip |
Core tip: Many new agents are being studied that may improve outcomes after renal transplantation. Potential improvements to the calcineurin inhibitor class include a recently Food and Drug Administration approved, prolonged release tacrolimus formulation and voclosporin, a cyclosporine analog. A novel, fully-human anti-CD40 monoclonal antibody, ASKP1240, is currently enrolling patients in phase 2 trials with calcineurin minimization and avoidance regimens. Novel treatments for antibody mediated rejection include bortezomib and eculizumab. |
Publish Date |
2013-12-31 17:17 |
Citation |
Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68-77 |
URL |
http://www.wjgnet.com/2220-3230/full/v3/i4/68.htm |
DOI |
http://dx.doi.org/10.5500/wjt.v3.i4.68 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345